Back to Browse Journals » Core Evidence » Volume 2 » Issue 1

Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer

Authors Sonya Haslam, Paul Chrisp

Published Date March 2007 Volume 2007:2(1) Pages 0—0

DOI http://dx.doi.org/10.2147/CE.S7418

Published 31 March 2007

Sonya Haslam, Paul Chrisp

Core Medical Publishing, Knutsford, UK

Introduction: Lung cancer is the leading cause of cancer-related mortality. Platinum-based chemotherapy is the usual first-line treatment for advanced nonsmall cell lung cancer (NSCLC), although an efficacy plateau has been reached with this approach. Bevacizumab is a recombinant, humanized, monoclonal antibody to vascular endothelial growth factor, which inhibits tumor angiogenesis and is being evaluated as a different mechanism to improve outcomes in patients with stage IIIB/stage IV (metastatic) NSCLC.

Aims: To review the emerging evidence for the potential use of bevacizumab in stage IIIB/IV NSCLC.

Evidence review: Adding bevacizumab to carboplatin plus paclitaxel improves response rates and significantly prolongs time to disease progression, which translates into a significant extension of overall survival (median 2.3 months in one key study). Low levels of intracellular adhesion molecule-1 are associated with better response. Preliminary evidence suggests that combining bevacizumab with erlotinib could improve outcomes in patients relapsing following platinum-based chemotherapy. Episodes of bleeding (particularly pulmonary hemorrhage) are the predominant adverse events associated with bevacizumab, probably a result of tumor disintegration. There is limited evidence that the high acquisition cost of bevacizumab unfavorably affects assessment of its cost effectiveness, although there are few other treatment options in these patients with poor prognosis.

Place in therapy: The encouraging results obtained with bevacizumab in patients with NSCLC are leading to its adoption in some treatment guidelines. Emerging evidence indicates improved outcomes when bevacizumab is added to carboplatin/paclitaxel in previously untreated patients with NSCLC, and when used with erlotinib in patients who have relapsed following platinum-based chemotherapy.

Key words: bevacizumab, evidence, nonsmall cell lung cancer

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Louise Profit, Paul Chrisp, Carole Nadin

Core Evidence 2008, 3:0-0

Published Date: 31 December 2008

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome

Mark Waterlow, Paul Chrisp

Core Evidence 2007, 2:0-0

Published Date: 29 February 2008

Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis

Louise Profit, Paul Chrisp

Core Evidence 2007, 2:0-0

Published Date: 30 November 2007

Maraviroc: the evidence for its potential in the management of HIV

Louise Profit

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Etanercept in psoriasis: the evidence of its therapeutic impact

Andrew Thomson

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting

Paul Chrisp

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Perindopril: the evidence of its therapeutic impact in hypertension

Andrew Thomson, Mary Greenacre

Core Evidence 2007, 2:0-0

Published Date: 31 March 2007

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia

Louise Profit

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

Ciclesonide in persistent asthma: the evidence of its therapeutic value

Charlotte A. Kenreigh, Linda Timm Wagner, Paul Chrisp

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

Aripiprazole: the evidence of its therapeutic impact in schizophrenia

William Winlow, Louise Profit, Paul Chrisp

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

Bortezomib: the evidence of its clinical impact in multiple myeloma

Simon Lancaster

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006

K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome

Margaret Duggan-Keen

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 31 March 2006

Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes

Joanne Knowles

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 31 March 2006

FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value

Andrew Thomson

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 31 March 2006

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes

Louise Profit

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Topiramate: the evidence for its therapeutic value in the prevention of migraine

Carole Nadin

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction

Carole Nadin

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 30 June 2005

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia

Sonya Haslam

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Aliskiren in hypertension: evidence for its potential therapeutic value

Doris Peter

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes

William Winlow

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value

Carole Nadin

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes

Andrew Thomson

Core Evidence 2005, 1-Issues 1 & 2:0-0

Published Date: 31 March 2005

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010